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Bacterial vaginosis (BV) is the most common genital tract infection in women during
their reproductive years and it has been associated with serious health complications,
such as preterm delivery and acquisition or transmission of several sexually transmitted
agents. BV is characterized by a reduction of beneficial lactobacilli and a significant
increase in number of anaerobic bacteria, including Gardnerella vaginalis, Atopobium
vaginae, Mobiluncus spp., Bacteroides spp. and Prevotella spp.. Being polymicrobial in
nature, BV etiology remains unclear. However, it is certain that BV involves the presence
of a thick vaginal multi-species biofilm, where G. vaginalis is the predominant species.
Similar to what happens in many other biofilm-related infections, standard antibiotics,
like metronidazole, are unable to fully eradicate the vaginal biofilm, which can explain the
high recurrence rates of BV. Furthermore, antibiotic therapy can also cause a negative
impact on the healthy vaginal microflora. These issues sparked the interest in developing
alternative therapeutic strategies. This review provides a quick synopsis of the currently
approved and available antibiotics for BV treatment while presenting an overview of novel
strategies that are being explored for the treatment of this disorder, with special focus on
natural compounds that are able to overcome biofilm-associated antibiotic resistance.
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INTRODUCTION
The healthy vaginal microflora has been described as being constituted mainly by Gram-positive
bacilli of the genus Lactobacillus, being L. crispatus, L. iners, L. gasseri, and L. jensenii the most
common species (Ravel et al., 2011). However, other non-beneficial microbial species, including
Gardnerella vaginalis, Enterococcus spp., and Prevotella spp., can be present in small numbers, not
sufficient to cause disease (Marrazzo et al., 2002). Importantly, lactobacilli play a pivotal role in
maintaining the female genital tract health while preventing genitourinary infections (Borges et al.,
2014).
Among genital infections, bacterial vaginosis (BV) is the leading vaginal disorder in women of
childbearing age, contributing to more than 60% of all vulvovaginal infections (Sobel, 2000). BV, as
Abbreviations: BV, Bacterial Vaginosis; CDC, Centers for Disease Control and Prevention; LAE, Lauramide Arginine Ethyl
Ester.
Machado et al. Bacterial Vaginosis Anti-Biofilms Treatments
a whole, has been associated with serious health problems,
including pre-term birth (Leitich et al., 2003), spontaneous
abortion (Guerra et al., 2006), pelvic inflammatory disease
(Rothman et al., 2003), endometritis (Jacobsson et al., 2002)
and acquisition and transmission of several sexually transmitted
agents (Gallo et al., 2012). Clinically, a profuse vaginal discharge
and a rotten fish vaginal odor are characteristic symptoms,
although some women with BV remain asymptomatic (Koumans
et al., 2007). Microbiologically, this condition is characterized
by a dramatic shift of vaginal microflora which involves the
loss of beneficial bacteria (lactobacilli) and a simultaneous
proliferation of anaerobic bacteria including G. vaginalis,
Atopobium vaginae, Mobiluncus spp., Bacteroides spp., and
Prevotella spp. (Verhelst et al., 2004). Its high prevalence and
the associated complications make BV an important public
health issue. However, due to the great diversity and complexity
of microorganisms involved, the BV etiopathogenesis is not
yet fully understood and is still a matter of controversy
(Schwebke et al., 2014).
Back in 1955, Gardner and Dukes proposed that G. vaginalis
was the sole etiological agent of BV (Gardner and Dukes,
1955). However, their findings were disputed when some years
later G. vaginalis was found in approximately 40% of healthy
women. In addition, other anaerobic bacteria were positively
associated with BV and this lead researchers to conclude that BV
was a polymicrobial infection (Sobel, 2000). However, a major
conceptual problem with this later hypothesis is its inconsistency
with epidemiological data, which suggests that BV is a sexual
transmitted disease and therefore, most likely to be caused
by a single agent (Josey and Schwebke, 2008). Currently, is
consensual that BV involves the presence of a dense, structured
and polymicrobial biofilm, primarily constituted by G. vaginalis
clusters, strongly adhered to the vaginal epithelium (Swidsinski
et al., 2005). Biofilms are communities of microorganisms
attached to a surface and encased in a polymeric matrix
of polysaccharides, proteins and nucleic acids (Høiby et al.,
2011). Due to the fact that bacteria within biofilms are not
effectively eliminated by the immune system (Cerca et al.,
2006; Xie et al., 2012) or fully destroyed by antibiotics (Cerca
et al., 2005; Tobudic et al., 2012), biofilm-related infections
tend to persist and so, not surprisingly, BV tends to have a
high rate of relapse and recurrence (Bradshaw et al., 2006).
So, the current paradigm is that the establishment of a G.
vaginalis biofilm is a required event for initiation and progression
of BV (Machado and Cerca, 2015). In fact, in vitro studies
demonstrated that G. vaginalis biofilm displays a high resistance
to the protective mechanisms of normal vaginal microflora,
including hydrogen peroxide, and lactic acid produced by
lactobacilli (Patterson et al., 2007), as well as an increased
tolerance to antibiotics (Swidsinski et al., 2008). Therefore,
vaginal biofilms play a key role not only in BV pathogenesis,
but also in its treatment failure and recurrence. Thus, the
purpose of this review is to present currently approved and
available therapeutic strategies for BV, as well as to discuss the
emerging therapies that are being explored for BV treatment,
attributing more emphasis to novel therapeutics targeting vaginal
biofilms.
CURRENT BV ANTIBIOTIC THERAPEUTIC
OPTIONS
Despite the most recent discoveries related to the etiology
of BV, current treatment is still directed toward alleviation
of symptoms through reduction of BV-associated bacteria
overgrowth and restoration of normal vaginal flora (Pirotta et al.,
2009). The Centers for Disease Control and Prevention (CDC)
recommends that all symptomatic women should be treated,
since it recognizes several benefits of therapy, including the relief
of the symptoms and signs of infection (Centers for Disease
Control and Prevention, 2015) and the reduction in the risk of
acquiring sexually transmitted diseases (Brotman et al., 2010).
Conventionally, BV is treated with metronidazole, clindamycin
or tinidazole (Centers for Disease Control and Prevention, 2015).
Presently, metronidazole is considered to be the drug of
choice for BV treatment (Centers for Disease Control and
Prevention, 2015). It is a first generation nitroimidazole, which
was initially indicated for the management of trichomoniasis
(Moffett and Mcgill, 1960) but was then shown to be effective
against anaerobic microorganisms (Tally et al., 1975). However,
metronidazole therapy is associated with several side effects such
as nausea, vomiting and gastrointestinal complaints (Schwebke
and Desmond, 2011; Abdali et al., 2015; Chavoustie et al., 2015;
Schwebke et al., 2015). Clindamycin is also an antimicrobial agent
for BV treatment (Centers for Disease Control and Prevention,
2015), with similar efficacy as metronidazole (Paavonen et al.,
2000; Beigi et al., 2004). It is a lincosamide that is available in
various pharmaceutical formulations including vaginal dosage
forms and oral (systemic) pills(Menard, 2011). However, when
applied topically, clindamycin might weaken latex products such
as condoms (Rosen and Rosen, 1999) and may even cause
pseudomembranous colitis (Trexler et al., 1997). Tinidazole was
themost recently approved antimicrobial agent for BV treatment,
by the Food and Drug Administration (Dickey et al., 2009)
and it is considered an alternative antimicrobial agent for BV
treatment particularly whenever metronidazole and clindamycin
are unavailable or not tolerated (Centers for Disease Control
and Prevention, 2015). Being a second generation nitroimidazole
with a longer half-life than metronidazole (Wood and Monro,
1975) it requires lower dosages, to be taken less frequently
than metronidazole (Dickey et al., 2009). Other antibiotics like
ornidazole (Thulkar et al., 2012), secnidazole (Núñez andGómez,
2005; Bohbot et al., 2010; Thulkar et al., 2012) and azithromycin
(Nikolov et al., 2008) have been tested as alternatives to treat BV,
however these antibiotics are not currently approved by the Food
and Drug Administration and have not shown to increase BV
cure rates.
Despite the high cure rates achieved in some studies, very high
BV recurrence rates and some relevant treatment side effects have
been reported. A list of the most recent studies (2010–2015) is
presented in Table 1.
The low efficacy of antibiotics in preventing recurrences is
thought to be due to their inability to fully eradicate BV vaginal
biofilms-associated bacteria. In fact, Swidsinski and colleagues
investigated the influence of oral metronidazole therapy on
G. vaginalis biofilms and reported that biofilms were only
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temporarily suppressed, and that in most cases rapidly regained
activity following treatment cessation (Swidsinski et al., 2008).
Later, Alves and colleagues determined the in vitro susceptibility
of 30 BV-associated biofilm forming bacteria to metronidazole,
tinidazole, and clindamycin and showed that all tested bacteria
tested were resistant to metronidazole and tinidazole and
67% to clindamycin (Alves et al., 2014). In this sense, novel
antimicrobials agents, with the ability to selectively target vaginal
pathogens and their biofilms, are urgently required.
EMERGING THERAPEUTIC ALTERNATIVES
AGAINST BV
The increasing evidence that BV is a biofilm-mediated infection
sparked the interest of the scientific community in exploring
agents aimed to disrupting biofilms. Thus, in recent years, studies
of anti-BV agents started to include biofilm disruptor candidates,
such as DNases, retrocyclins, probiotics, antiseptics, natural
antimicrobials, and plant-derived compounds (see Table 2).
Antiseptics
During several decades, antiseptics have been applied in the
management of vaginal infections (Ratzan, 1969; Ison et al.,
1987). They have an antibacterial activity against a broad
spectrum of bacteria, acting by nonspecifically disrupting their
cell membrane (Lachapelle et al., 2013). A great panoply of
antiseptics have been used to treat BV, including dequalinium
chloride (Petersen et al., 2002), povidone iodide (Wewalka
et al., 2002), hydrogen peroxide (Cardone et al., 2003),
polyhexamethylene biguanide (Gerli et al., 2003), chlorhexidine
(Molteni et al., 2004), octenidine hydrochloride/phenoxyethanol
(Novakov Mikic and Budakov, 2010), nifuratel (Togni et al.,
2011), and benzydamine hydrochloride (Boselli et al., 2012).
However, a recent systematic review verified that most studies
addressing the use of antiseptics for BV treatment are
somehow methodologically weak since follow-up studies were
very limited and their safety and excipients composition was
poorly investigated (Verstraelen et al., 2012). Nevertheless,
the potential of antiseptics against BV biofilms was recently
highlighted when Swidsinski and colleagues reported high initial
cure rates when using octenidine. However, the efficacy of
prolonged and repeated treatment was lower than expected and
bacterial resistance emerged in a considerable subset of women
(Swidsinski et al., 2015).
Probiotics and Prebiotics
An alternative approach to deal with BV is by modulating the
vaginal microbiota, for example, by using probiotics. Probiotics
are live microorganisms which confer a health benefit to the
host, when administered in suitable amounts (Food Agriculture
Organization of the United Nations World Health Organization,
2001). In the human vagina, certain Lactobacillus strains can act
as probiotics, preventing the growth of BV-associated bacteria
through two main mechanisms: the inhibition of pathogens
adhesion to vaginal epithelium (Machado et al., 2013); and
the production of antimicrobial compounds like hydrogen
peroxide (Mastromarino et al., 2002), lactic acid (Boskey et al.,
2001) and bacteriocins (Aroutcheva et al., 2001b). Diverse
pharmaceutical formulations containing probiotic lactobacilli
strains have reduced BV symptoms, improved the vaginal
microflora profile, being usually well-tolerated (Rossi et al.,
2010; Hantoushzadeh et al., 2012; Facchinetti et al., 2013; Vujic
et al., 2013; Vicariotto et al., 2014). In contrast, despite their
therapeutic potential, some clinical trials have not detected a
significant improvement in BV management (Falagas et al.,
2007). Alternatively, probiotics have been proposed as adjuvants
to antibiotic therapy. Several combinations of metronidazole,
clindamycin or tinidazole with lactobacilli probiotic preparations
have displayed promising results in BV treatment since they have
been associated with high cure rates, low recurrence or quick
re-establishment of an healthy vaginal microflora (Marcone
et al., 2010; Bodean et al., 2013; Recine et al., 2016). Probiotics
have also been used in an attempt to specifically deal with
BV biofilms. Remarkably, in 2007, Saunders and colleagues
showed that L. reuteri RC-14 was able to disrupt in vitro G.
vaginalis biofilms (Saunders et al., 2007). Later, McMillan and
colleagues demonstrated that probiotic L. reuteri RC-14 and L.
rhamnosus GR-1 were able to incorporate themselves into BV-
biofilm, composed by G. vaginalis and A. vaginae, causing both
the disruption of the biofilm structure and bacterial cell death
(McMillan et al., 2011). These findings provide some evidence
of how lactobacilli probiotics might interfere with an abnormal
vaginal microflora, reinforcing the hypothesis that probiotics
could eradicate vaginal pathogenic biofilms and restore the
normal microflora in in vivo situations.
It has also been proposed that prebiotics, nutritional
substances that stimulate the growth of probiotics, could
be used as alternative to treat BV (Roberfroid, 2007).
Interestingly, Rousseau and colleagues demonstrated that
prebiotic preparations containing oligosaccharides were able to
promote the growth of beneficial lactobacilli strains but not of the
pathogenic microorganisms often found in urogenital infections
including G. vaginalis (Rousseau et al., 2005). Later, Zeng and
colleagues compared the efficacy of a prebiotic gel containing
sucrose with 0.75% metronidazole vaginal gel to treat BV (Zeng
et al., 2010). In that study, the prebiotic gel displayed a similar
therapeutic cure rate to metronidazole, having a major advantage
of quicker restoration of the normal vaginal microflora. Recently,
Coste and colleagues evaluated the efficacy and safety of another
prebiotic gel, applied as adjuvant therapy, in women treated for
BV and showed an improved recovery of the normal vaginal
flora, reducing the risk of recurrences (Coste et al., 2012).
Plant-Derived Compounds
The use of plant-derived compounds in the treatment of genital
infections is another therapy on the rise (Palmeira-de-Oliveira
et al., 2013). One of the earliest reports on this topic dates
back from 1991, when Blackwell described the first therapeutic
success of using plants extracts to treat BV (Blackwell, 1991).
Subsequently, several clinical trials have demonstrated that the
use of plant-derived compounds promoted the reduction of BV
symptoms and are associated with high cure rates and tolerability,
including a polyherbal vaginal pessary (Patel et al., 2008), vaginal
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cream containing Zataria multiflora (Abdali et al., 2015), a
vaginal douche of thymol and eugenol (main constituents of
thyme oil and clove oil; Sosto et al., 2011), watery extract
of Triticum vulgare (Boselli et al., 2012) and garlic tablets
(Mohammadzadeh et al., 2014). Surprisingly, up to now only
one study evaluated the capability of plant-derived compound to
eradicate BV biofilms. Interestingly, Braga and colleagues showed
that thymol, a molecule present in thyme essential oil, had an
inhibitory effect upon both newly formed andmatureG. vaginalis
biofilms, which supports the importance of exploring essential
oils and their main constituents as therapeutic alternative to
treat BV (Braga et al., 2010). Furthermore, the expectations
on essential oils as effective agents against BV-biofilms can be
inferred from studies in other related vaginal biofilms (Palmeira-
de-Oliveira et al., 2012; Bogavac et al., 2015).
Natural Antimicrobials
Natural antimicrobials, mainly bacteriocins, have also been
studied as potential therapeutic alternatives against BV. Several
natural antimicrobials, including L. acidophilus 160 bacteriocin
(Aroutcheva et al., 2001a), subtilosin (Sutyak et al., 2008,
2012; Cavera et al., 2015), lactocin 160 (Turovskiy et al.,
2009), lactosporin (Riazi et al., 2012), fermenticin HV6b (Kaur
et al., 2013), polylysine (Sutyak et al., 2012; Cavera et al.,
2015), lauramide arginine ethyl ester (LAE) (Cavera et al.,
2015; Sutyak et al., 2012) and glycerol monolaurate (Strandberg
et al., 2010; Sutyak et al., 2012), displayed an inhibitory effect
against BV-associated bacteria grown planktonically, usually not
affecting the lactobacillary flora. Due to this important advantage,
natural antimicrobials have also been proposed as a valuable
therapeutic alternative to eradicate BV-biofilms. Remarkably,
Turovskiy and colleagues tested the susceptibility of G. vaginalis
biofilms to several natural antimicrobials. Using a series of
in vitro assays, these researchers demonstrated that LAE had
the strongest bactericidal effect against G. vaginalis biofilms,
proposing LAE as a potential natural agent to disrupt BV-
biofilm (Turovskiy et al., 2012). Later, Algburi and colleagues
showed that subtilosin and LAE showed synergistic effect
with clindamycin and metronidazole, inhibiting G. vaginalis
biofilms, while not disturbing vaginal lactobacilli (Algburi et al.,
2015). This demonstrated that the combination of conventional
antibiotics with natural antimicrobials can improve the cure
rates of antibiotic therapy, especially in cases where antimicrobial
resistant was found.
Acidifying/Buffering Agents
Another interesting approach to treat BV is vaginal acidification
(Boskey et al., 1999). However, the results concerning this
strategy are controversial since acidification strategies alone,
using acetic acid (Holley et al., 2004) or acid-buffering
formulation (Simoes et al., 2006) showed to be somewhat
ineffective against BV. Recently, Bahamondes and colleagues
verified that a soap containing lactic acid and lactoserum could be
used for external intimate hygiene, reducing BV recurrence after
treatment with oral metronidazole (Bahamondes et al., 2011).
Interestingly, vitamin C, when coated with silicon, allowed the
constant release of the active agent, resulting in a long-lasting
vaginal low pH and prevention of vaginal irritation (Polatti
et al., 2006). Other studies reported an effective and safe
use of vaginal vitamin C tablets in BV treatment (Petersen
et al., 2011), contributing to improve abnormal vaginal pH and
microflora, especially in pregnant women (Zodzika et al., 2013).
Additionally, the regular use of vitamin C during 6 days per
month, for 6 months after successful BV treatment, was shown
to decrease the risk of BV recurrence (Krasnopolsky et al.,
2013). Another alternative comes in the form of buffering agents.
Polycarbophil is a weak poly-acid that it is able to adhere to
vaginal epithelial cells, acting as a buffer in the vaginal secretions
(Milani et al., 2000). Recently, a new benzoyl peroxide formulated
polycarbophil/carbopol 934P hydrogel was shown to inhibit the
growth of G. vaginalis with little or no effect on Lactobacillus
spp. (Xu et al., 2013). Another agent that has been long used in
the treatment of vaginal infections is boric acid (Van Slyke et al.,
1981). Recently, Reichman and colleagues reported that the use
of boric acid in combination with a nitroimidazole reduce the BV
recurrence (Reichman et al., 2009), suggesting a potential impact
on BV biofilms. However, this need to be further studied and
in vitro biofilm experiments will elucidate the role of boric acid
in BV prevention.
Other Anti-Biofilm Agents
An innovative approach to disrupt BV biofilms consists in the
use of DNase which targets extracellular DNA. According to
Hymes and colleagues, G. vaginalis biofilms contain extracellular
DNA, which is essential to their structural integrity. In a series
of in vitro studies, they showed that enzymatic disruption of
extracellular DNA not only inhibited the formation of new
biofilms but also destroyed the already formed ones (Hymes
et al., 2013). In addition, DNase liberates bacteria from biofilms
into the supernatant fractions and so potentiates the effect of
metronidazole. Furthermore, using a murine model of vaginal
colonization of G. vaginalis, these researchers also demonstrated
that DNase treatment decreases the colonization density of G.
vaginalis. Thus, DNase seems to be a promising therapeutic agent
for BV either alone or in combination with antibiotics.
Another strategy involves the use of retrocyclin 101, a
synthetic cyclic antimicrobial peptide with antiviral activity (Cole
et al., 2007). Retrocyclin 101 and has been shown to inhibit the
cytolytic activity of vaginolysin, a toxin produced by G. vaginalis,
and to prevent de novo biofilm formation of this bacterial species
(Hooven et al., 2012) while being well-tolerated by host tissues
and by commensal vaginal bacteria (Eade et al., 2013).
CONCLUSIONS AND FUTURE
DIRECTIONS
BV current approved therapies are not sufficient to deal with this
multi-species biofilm-related vaginal disorder. Future, research
should address biofilm communities with a particular emphasis
on multi-species biofilms, a topic that only recently emerged
(Castro and Cerca, 2015). By properly addressing the complex
interactions established in multi-species biofilms, novel strategies
will hopefully overcome the high recurrence and relapse rates
associated with BV.
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